Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
News about Daré Bioscience, Inc. (NASDAQ: DARE) centers on its efforts to advance and commercialize women’s health products across contraception, sexual health, vaginal health and menopause. Company press releases highlight progress on clinical programs, grant-funded research, regulatory interactions and commercialization plans for both prescription and consumer health offerings.
Recent news has focused on DARE to PLAY Sildenafil Cream, a proprietary topical arousal cream designed specifically for women. Daré reports that this first-of-its-kind topical sildenafil formulation for women has been evaluated in multiple clinical studies and is being introduced via a Section 503B outsourcing facility as an evidence-backed option to enhance genital blood flow and arousal response. Updates describe pre-order availability in select U.S. states, webinar events with sexual health clinicians and the role of DARE to PLAY in the company’s broader 503B compounding strategy.
Another major news theme is Ovaprene, Daré’s investigational hormone-free monthly intravaginal contraceptive. Releases discuss interim Phase 3 results, data safety monitoring board recommendations to continue the pivotal study without modification, and the return of commercialization rights to Daré from a prior license partner. These items provide context on clinical progress, safety and tolerability findings, and the company’s plans to maximize the asset’s value.
Daré’s news flow also covers non-dilutive grant funding and collaborations, including multi-year support for DARE-LARC1, a long-acting contraceptive based on the DARE-IDDS programmable drug delivery platform, and grants for non-hormonal intravaginal contraceptive research and HPV-related programs. Corporate updates detail quarterly financial results, Nasdaq listing matters, and strategic initiatives that combine near-term revenue opportunities with long-term pipeline development. Investors and observers can use the DARE news page to follow these developments and track how clinical, commercial and funding milestones evolve over time.
Daré Bioscience (NASDAQ: DARE) reported its financial results for Q2 2022, highlighting a $32.1 million cash position and a $10 million revenue recognition from a licensing agreement with Organon for XACIATO, an FDA-approved treatment for bacterial vaginosis. The company expects to launch XACIATO in the U.S. in Q4 2022. Ongoing clinical studies for DARE-VVA1 and DARE-HRT1 are also on track for topline data in the fourth quarter. General and administrative expenses increased to $2.8 million, while research and development expenses decreased slightly to $6.8 million.
Daré Bioscience (NASDAQ: DARE) will host a conference call and live webcast on August 9, 2022, at 4:30 p.m. ET, to discuss its financial results for Q2 2022 and company updates. Investors can access the call by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international), using conference ID 3817141. The call will also be available on the company’s website and will replay until August 23, 2022. Daré focuses on innovative women's health products, including its FDA-approved XACIATO™ and various candidates in development.
Daré Bioscience, Inc. (NASDAQ: DARE) announced that its President and CEO, Sabrina Martucci Johnson, will participate in a virtual panel titled "A Tipping Point in Women’s Health" on July 13, 2022, at 11:00 a.m. ET. The panel, hosted by Maxim Group LLC on M-Vest, will discuss the implications of recent SCOTUS outcomes on contraception. Other panelists include CEOs from Agile Therapeutics and Femasys. An archived webcast will be available from July 15-28, 2022. Daré Bioscience focuses on innovative women’s health products, including FDA-approved XACIATO™ for bacterial vaginosis.
Daré Bioscience (NASDAQ: DARE) has finalized an exclusive licensing agreement with Organon for XACIATO, a treatment for bacterial vaginosis, which affects approximately 21 million American women. Daré will receive a $10 million upfront payment, with opportunities for milestone payments totaling up to $182.5 million and tiered royalties based on net sales. XACIATO is expected to be commercially available in the U.S. in Q4 2022. This collaboration aims to enhance the treatment options available to women suffering from this condition.
Daré Bioscience announced the partial adjournment of its 2022 Annual Meeting, focusing on Proposal 5, which seeks to increase authorized shares to 240 million. While all director nominees and Proposals 2, 3, 4, and 6 were approved, Proposal 5 did not receive enough votes. The meeting will reconvene on July 14, 2022, to further solicit votes. Currently, only 49.2% of outstanding shares voted in favor. Two proxy advisory firms have recommended voting for Proposal 5. The company stresses that flexibility in capital structure is crucial for future growth.
SAN DIEGO, June 6, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience (NASDAQ: DARE) announced President and CEO, Sabrina Martucci Johnson, will participate in a panel and present at the 2022 BIO International Convention in San Diego from June 13-16, 2022. The panel titled "Primed for Growth: Innovating to Address the Business Opportunity in Building a Women’s Health Market" is scheduled for June 13, 2022, at 2:15 PM PT. The women’s health market is projected to reach $24.5 billion by 2027, growing at a 12.5% CAGR.
Daré Bioscience announced that CEO Sabrina Martucci Johnson will participate in a virtual fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022. The conference will be held both in-person at the Fountainebleau Miami Beach Hotel and virtually. The chat will be available on-demand starting May 24, 2022, at 7:00 a.m. Eastern Time, with an archived version accessible until June 7, 2022. Daré focuses on innovative women's health products, notably XACIATO, a treatment for bacterial vaginosis.
Daré Bioscience (NASDAQ: DARE) reported financial results for Q1 2022, with cash and cash equivalents of $39.3 million as of March 31, 2022. The company announced the initiation of the DARE-HRT1 Phase 1/2 clinical study in April 2022 and an exclusive global license agreement with Organon for XACIATO™, expected to close in Q2 2022. This agreement includes a $10 million cash payment to Daré and the U.S. commercial launch is anticipated in Q4 2022. However, the company's comprehensive loss increased to $8.4 million compared to $7.3 million in Q1 2021.
Daré Bioscience, Inc. (NASDAQ: DARE) has received a $249,000 grant from NICHD to support research aimed at understanding U.S. women's preferences for long-acting injectable (LAI) contraceptives. The study will survey around 1,000 women aged 18-44 to gather insights on user preferences and characteristics of LAI products. Daré is developing 6- and 12-month contraceptive formulations (ADARE-204 and ADARE-214) in collaboration with Adare Pharma Solutions, aiming to enhance user compliance and effectiveness over current options.
Daré Bioscience, Inc. (NASDAQ: DARE) has scheduled a conference call for May 12, 2022, at 4:30 p.m. ET to discuss its financial results for Q1 2022 and provide a company update. Investors can access the call by dialing (844) 831-3031 in the U.S. or (443) 637-1284 internationally. Daré is focused on women's health innovation with products like XACIATO for bacterial vaginosis and clinical candidates like Ovaprene for contraception. The company emphasizes transparency in communication regarding financials and product developments through various channels.
FAQ
What is the current stock price of Dare Bioscience (DARE)?
What is the market cap of Dare Bioscience (DARE)?
